PUBLISHER: IMARC | PRODUCT CODE: 1390644
PUBLISHER: IMARC | PRODUCT CODE: 1390644
The global botulinum toxin market size reached US$ 5.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.4 Billion by 2028, exhibiting a growth rate (CAGR) of 7.64% during 2022-2028.
Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum, which is an anaerobic, gram-positive, spore-forming rod commonly found in plants, soil, water, and intestinal tracts of animals. It plays a significant role in the management of a wide variety of medical conditions. These conditions include strabismus and focal dystonia, hemifacial spasm, headaches, hypersalivation, hyperhidrosis, and spastic movement disorders. Moreover, it is utilized in the treatment of various chronic diseases that respond partially to available medical treatments. Nowadays, it is also used for the cosmetic purpose of temporarily reducing frown lines, creases, and wrinkles on the face, chin, neck, and chest.
A significant rise in the prevalence and diagnosis of chronic and acute diseases represents one of the key factors bolstering the market growth. Botulinum toxin finds extensive applications in the treatment of dermatological conditions, such as overactive smooth muscles, abnormal activity of glands, and hyperhidrosis. Moreover, the rising beauty consciousness among individuals, along with their willingness to undergo reconstructive and cosmetic surgeries, is contributing to market growth. In addition, the emerging trend of cosmetic tourism, in confluence with the increasing influence of social media, rapid urbanization, and inflating per capita income, is influencing the market positively. Apart from this, as the skin becomes more susceptible to wrinkles and sagging with age, the growing geriatric population and the desire to retain young and healthy skin are bolstering the market growth. Furthermore, the development of new potent toxins by combining different serotypes can reduce the total units and overall antigenic dose and improve effectiveness and duration of effect. These advancements are projected to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global botulinum toxin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and end user.
Toxin Type A
Toxin Type B
Therapeutics
Aesthetics
Hospitals and Clinics
Dermatology Clinics
Spas and Cosmetic Centers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Eisai Co. Ltd, Evolus Inc, Galderma SA, HUGEL Inc., Ipsen Group, Medytox Inc., Merz Pharma GmbH & Co. KGaA, Metabiologics Inc. and Revance Therapeutics Inc.